A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...

According to the National Capital Poison Center, a not-for-profit poison control organization, at least 85 drugs—including ...

If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

The DVLA has the power to revoke your licence if you're taking certain medications - and it's not just about illegal drugs ...

A systematic review of existing medicines has found that antibiotics and vaccinations are associated with a reduced risk of ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...